Overview

Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Accelerated Community Oncology Research Network
Collaborators:
Celgene Corporation
Genentech, Inc.
Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Paclitaxel